Warp: You know I think I have come to that conclus

Warp: You know I think I have come to that conclusion, as well. I have been very perplexed about Gerald not responding to Jason's 1 million 2015 revenue estimate. Then when they announced this purchase, of another broke asset with huge potential, the "business model" of being a holding company where we buy stuff that's broken, fix it, and sell it for up front cash and royalties, long before revenue even becomes an issue....finally came into focus for me.

We've got Lympro, Eltoprazine, and now ESS that all fit that model. I suspect they make more purchases, and that is why they wanted the extra billion shares.

This is a very different paradigm shift from the LymPro revenue model that I've had in my mind, and which is why i bought into AMBS in the first place.

This could be an interesting model. Change is hard, but obviously, Gerald is not really interested in promoting Lympro and focusing on revenue.